Comparative Pharmacology
Head-to-head clinical analysis: CAVERJECT versus DINOPROSTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAVERJECT versus DINOPROSTONE.
CAVERJECT vs Dinoprostone
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Causes relaxation of corpus cavernosum smooth muscle and vasodilation via increased intracellular cyclic guanosine monophosphate (cGMP) due to inhibition of phosphodiesterase type 5 (PDE5) by its active metabolite, alprostadil.
Prostaglandin E2 (PGE2) agonist; stimulates uterine smooth muscle contractions, promotes cervical ripening by increasing collagenase activity and softening connective tissue, and induces gap junction formation between myometrial cells.
Initial dose 2.5 micrograms intracavernous injection, titrate to effect; maximum 60 micrograms per injection. Frequency no more than 3 times per week with at least 24 hours between doses.
Cervical ripening: 0.5 mg dinoprostone gel (Prepidil) intracervically every 6 hours as needed, max 3 doses in 24 hours; or 10 mg vaginal insert (Cervidil) placed transversely in posterior vaginal fornix, removed after 12 hours or at onset of active labor. Termination of pregnancy: 20 mg vaginal suppository (Prostin E2) every 3-5 hours until abortion, max 240 mg total.
None Documented
None Documented
Clinical Note
moderateDinoprostone + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Dinoprostone."
Clinical Note
moderateDinoprostone + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Dinoprostone."
Clinical Note
moderateDinoprostone + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Dinoprostone."
Clinical Note
moderateTiaprofenic acid + Dinoprostone
Terminal elimination half-life is 1-2 hours; clinically, plasma levels decline rapidly after injection, with minimal systemic accumulation.
Terminal elimination half-life is 2.5-5 minutes due to rapid metabolism in the lungs; clinical effects persist longer due to tissue binding.
Renal: 70-80% as metabolites, 20-30% unchanged; biliary/fecal: <5%
Approximately 90% metabolized in the lung, liver, and kidney; metabolites excreted in urine (primary) and feces. Less than 1% excreted unchanged in urine.
Category C
Category A/B
Prostaglandin
Prostaglandin
"The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tiaprofenic acid."